Daily FNArena News - Small Caps

A lack of junior miner exploration in tough economic times has weighed on drill supplier Imdex, but brokers believe an upswing is not too far off

Amplia Therapeutics is in pursuit of a cancer drug for pancreatic cancer and possibly other indications including ovarian cancer, the New Criterion’s Tim Boreham reports

With the Big Four banks regarded as overvalued, investors are pondering whether there’s better value in their smaller counterparts that trade on more modest valuations but with similar or higher dividend yields

Recently ASX-listed Blinklab claims the world’s best mobile phone app for detecting autism, the New Criterion’s Tim Boreham reports

ARB Corp’s third-quarter performance showcased why shares continue to trade at a premium to the Small Industrials Index

Following a strong run over the last year, brokers see further upside for shares of FleetPartners following first half results

Life360 has doubled in share price since its March earnings result, but brokers believe further re-rating is still on the cards

As per the New Criterion’s Tim Boreham, Invion is an old company on a new mission

SiteMinder’s March quarter update showed the company is on track to reach positive earnings and cash flow next quarter and new product launches offer growth

The New Criterion’s Tim Boreham uncovers the potential of 4D Medical in the USA